Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Who is this study for? Patients with Prodromal Schizophrenia
What treatments are being studied? NMDA-Enhancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 13
Maximum Age: 45
Healthy Volunteers: f
View:

• Individuals meeting Criteria of Prodromal Syndrome (at least one of the following: 1. attenuated positive symptoms; 2. brief intermittent psychotic symptoms; 3. genetic risk and deterioration).

• Subjects remain symptomatic (scoring at least 20 on the Scale of Prodromal Symptoms \[SOPS\] total score) after the 6-week screening phase (which contains the health-promotion program) and before the 12-week drug-trial period.

• Subjects may be receiving ongoing treatment with antipsychotic medications, or may be medication-free for at least 12 weeks.For the subjects who have already been on such medications, the medications need to be continued for at least 4 weeks before the screening phase and the doses need to be kept unchanged during the study period. For those who have not yet been on such medications, these medications are forbidden during the study period.

• Subjects agree to participate in the study and provide written informed consent after complete description of the study. For the subject \< 20 years old, a parent also has to provide written informed consent.

Locations
Other Locations
Taiwan
Department of Psychiatry, China Medical University Hospital
RECRUITING
Taichung
Contact Information
Primary
Hsien-Yuan Lane, M.D., Ph.D
hylane@gmail.com
886 4 22052121
Time Frame
Start Date: 2021-11-01
Estimated Completion Date: 2026-12
Participants
Target number of participants: 48
Treatments
Experimental: NMDAE
An NMDA enhancer
Placebo_comparator: Placebo
Placebo
Related Therapeutic Areas
Sponsors
Leads: China Medical University Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials